Omeros (NASDAQ:OMER) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
OMER has been the subject of a number of other research reports. HC Wainwright set a $30.00 target price on shares of Omeros and gave the company a “buy” rating in a research report on Thursday, December 14th. Maxim Group set a $24.00 target price on shares of Omeros and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Cowen cut shares of Omeros from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. Finally, Zacks Investment Research cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $30.38.
Shares of Omeros (OMER) traded down $2.40 during trading on Wednesday, hitting $11.25. 5,700,000 shares of the stock were exchanged, compared to its average volume of 730,690. The company has a market capitalization of $540.04, a PE ratio of -8.72 and a beta of 3.30. Omeros has a 52 week low of $10.51 and a 52 week high of $27.09. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.